IFM Therapeutics has appointed Michael Cooke to serve as its chief scientific officer, the same position he held most recently at Magenta Therapeutics. Before Magenta, Cooke was a founding scientist at the Genomics Institute of the Novartis Research Foundation, where he held several positions. Last month, Boston-based IFM raised $55.5 million to launch its third drug subsidiary and an incubator, both focused on developing treatments for inflammatory diseases and cancers.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
